Ikaria® Names New Chief Financial Officer

HAMPTON, N.J., Oct. 11, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced that Tasos G. Konidaris has joined the Company as Senior Vice President and Chief Financial Officer (CFO).  Mr. Konidaris succeeds Craig Tooman, who left the Company in early 2011 to pursue other interests.

"I am delighted that Tasos has joined us in this key position, and I am confident that his strong experience in effectively managing the financial functions of global companies will benefit Ikaria," commented Daniel Tasse, Chairman and CEO of Ikaria. "The combination of a promising product pipeline and a well-run business, both financially and operationally, will help us achieve our vision of becoming a leader in critical care."

Mr. Konidaris has over 20 years of global financial and operational experience, most recently with Dun & Bradstreet (D&B) Corporation, where he was Senior Vice President and CFO since 2007.  Prior to joining D&B, Tasos served as Group Vice President at Schering Plough Corporation, which was acquired by Merck & Co. in 2010.  As Vice President and CFO of North America and Global Business Management at Pharmacia Corporation in 2003, he played a significant role in the integration of the global pharmaceutical groups of Pharmacia and Pfizer Inc.  His early career experience includes positions of increasing responsibility at Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris holds an MBA from Drexel University and a BS from Gwynedd Mercy College in Pennsylvania.

About Ikaria, Inc.

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications with INOMAX. Ikaria's late stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com.

SOURCE Ikaria, Inc.